Submit or Track your Manuscript LOG-IN

In vivo Anti Inflammation Studies of Novel 1, 2, 5 Oxadiazole Sulfonamide Hybrids

In vivo Anti Inflammation Studies of Novel 1, 2, 5 Oxadiazole Sulfonamide Hybrids

Hafiz Adnan Ahmad1,2*, Muhammad Aslam2, Salman Gul2, Tariq Mehmood2 and Munawar Ali Munawar2

1Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of Ministry of Education, Department of Chemistry and Materials Science, Northwest University, Xi’an 710069, People’s Republic of China
2Institute of Chemistry, University of the Punjab, Lahore 54590, Pakistan
 
* Corresponding author: adnan.ahmad.pu@hotmail.com

ABSTRACT

In present study we designed and synthesized a novel series of 1,2,5-oxadiazole-sulfonamide hybrids (4a-4j) in search of more potent anti-inflammatory agents. Title compounds were synthesized by chlorosulfonation of 3,4-diphenyl-1,2,5-oxadiazole (3) followed by condensation with amines and all derivatives were obtained in moderate to good yield. All synthesized hybrids were characterized with spectroscopic techniques and further evaluated for anti-inflammatory potential. The synthesized hybrids were screened in vivo by employing carrageenan-induced paw edema method at 10 mg/kg dose. Among all derivatives, two compounds 4g and 4b displayed better anti-inflammation potential than standard drugs celecoxib and indomethacin. While the anti-inflammation profile of compounds 4h, 4e and 4f during in vivo screening was also comparable to celecoxib and indomethacin. The structure-activity relationship (SAR) was also discussed with the reference of substituent nature. Present results showed that newly synthesized hybrids have significant anti-inflammatory potential and might be played an important role to the development of more potent anti-inflammation agents in future. 

 

To share on other social networks, click on any share button. What are these?

Pakistan Journal of Zoology

August

Vol. 54, Iss. 4, Pages 1501-2001

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe